Aetna to pay $86M in arbitration settlement to HCA Healthcare

One of the nation’s largest health insurers, Aetna, will pay $86 million to HCA Healthcare after a lawsuit stemming from 2015 led to an arbitration trial.

The case related to Aetna’s out-of-network benefit payment and administration practices in Florida for service and care provided to members in Aetna’s individual Public Exchange products from 2014 to 2016. According to Aetna, which is now owned by CVS Health, coverage under Aetna’s individual Public Exchange products in the sunshine state was not available until after Dec. 31, 2016, according to a public filing from CVS Health.

According to HCA, Aetna paid too little for services rendered to HCA hospitals that provided emergency room care to out-of-network patients with insurance purchased on the public exchange under the Affordable Care Act. HCA Healthcare is a Tennessee-based hospital and healthcare facilities operator and is a Fortune 500 company.

Last year, HCA Healthcare was awarded $150 million by the trial arbitrator. Aetna’s appeal brought that down to $86 million on March 28, 2019. CVS Health, which completed its $69 billion merger with Aetna at the end of 2018, indicated the settlement amount in its first quarter earnings report.

The lawsuit was not the only trouble for Aetna lately. The health insurer also recently settled out of court with a patient who sued over coverage denial in California and is facing another lawsuit from a Florida hospital over other claims of coverage denial.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.